Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy
- 1 March 2006
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 22 (3) , 232-239
- https://doi.org/10.1089/aid.2006.22.232
Abstract
Optimal adherence is essential for successful antiretroviral therapy. We analyzed the relation between minimum plasma drug concentration (C min) and total drug exposure over 24 hr (AUC24) with virologic failure for therapy-adherent patients in the nevirapine (NVP) and efavirenz (EFV) groups of the double nonnucleoside study (2NN), which compared the efficacy of NVP and/or EFV together with stavudine and lamivudine. The objective was to find cutoff values of the C min and AUC24 below which the risk of virologic failure increased. The relation between C min and AUC24 with virologic failure (never a plasma viral load [pVL] < 50 copies/ml or a rebound to two consecutive pVL > 50 copies/ml) was analyzed with proportional hazard analyses. Data were censored at end of study or change of allocated treatment. The risk of virologic failure with NVP (n = 511) started to increase at a C min < 3.1 mg/L (hazard ratio [HR], 1.33; 95% confidence interval [CI], 0.89–1.97), but there was no cutoff value below which a statistically significant increased risk occurred. Neither was such a cutoff point identified for the AUC24. The risk of virologic failure with EFV (n = 312) was significantly increased at a C min < 1.1 mg/L (HR, 1.95; 95% CI, 1.08–3.54) and an AUC24 < 40 mg · hr · L–1 (HR, 1.95; 95% CI, 1.07–3.54). Both cutoff values represent the median values for adherent patients. These associations were driven by patients from Thailand. Adjusting for geographical region made the association between C min and AUC24 with virologic failure statistically nonsignificant. The sensitivity of the C min values was too low (29% for NVP, 64% for EFV) to be an adequate predictor for virologic failure. We conclude that identifying the C min value for the sole purpose of predicting virologic failure in patients who report to be adherent to NVP or EFV is questionable because of the absence of a concentration–response relation (NVP) or the low sensitivity for such a cutoff value (NVP and EFV).Keywords
This publication has 34 references indexed in Scilit:
- GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy*HIV Medicine, 2004
- Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 cells/LAnnals of Internal Medicine, 2003
- Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individualsAIDS, 2003
- Low Nevirapine Plasma Concentrations Predict Virological Failure in an Unselected HIV-1-Infected PopulationClinical Pharmacokinetics, 2003
- Therapeutic Drug MonitoringDrugs, 2003
- PharmAdaptAIDS, 2002
- Position Paper on Therapeutic Drug Monitoring of Antiretroviral AgentsAIDS Research and Human Retroviruses, 2002
- Assessment of Adherence to HIV Protease Inhibitors: Comparison and Combination of Various Methods, Including MEMS (Electronic Monitoring), Patient and Nurse Report, and Therapeutic Drug MonitoringJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- The Consistency of Adherence to Antiretroviral Therapy Predicts Biologic Outcomes for Human Immunodeficiency Virus–Infected Persons in Clinical TrialsClinical Infectious Diseases, 2002
- A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse TranscriptaseNew England Journal of Medicine, 1993